MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

GPNMB protein levels in CNS are modulated by PD risk variant rs199347

Y. Seo, M. Diaz Ortiz, D. Weintraub, V. Van Deerlin, J. Trojanowski, A. Chen-Plotkin (Philadelphia, PA, USA)

Meeting: MDS Virtual Congress 2020

Abstract Number: 506

Keywords: Lysosomal disorders

Category: Parkinson's Disease: Genetics

Objective: This study evaluates protein quantitative trait loci (pQTL) effect of single nucleotide polymorphism (SNP) rs199347 in modulating glycoprotein non-metastatic melanoma protein B (GPNMB) expression and assesses GPNMB as potential biomarker for Parkinson’s disease (PD).

Background: Genome-wide association studies (GWAS) have shown a link between non-coding SNP rs199347 at the GPNMB locus and risk for PD [1]. Although rs199347 is known to be an expression QTL for GPNMB RNA in the central nervous system [2], it is not known whether rs199347 genotype modulates GPNMB protein expression. GPNMB protein levels have been reported to be a biomarker for Gaucher disease, a lysosomal storage disorder caused by GBA mutations [3], which also increase risk for PD [1]; however, the potential use of GPNMB as an idiopathic PD biomarker remains unexplored.

Method: PD patients were selected from the Penn Integrative Neurodegenerative Disease Database (INDD) based on clinical diagnosis, whereas controls had no known neurodegenerative disease. Cohorts were matched by age and sex. Plasma and CSF samples were obtained through the Center for Neurodegenerative Disease Research biobank. GPNMB levels were quantified by ELISA (R&D systems) and rs199347 genotype was determined by NeuroX SNP array or Global Screening array. Data were analyzed by linear or logistic regression, to adjusting for covariates.

Results: rs199347 genotype associated with GPNMB protein levels in the CSF regression (β=0.091 (p=9.34e-05)). GPNMB was significantly elevated in the plasma of PD patients compared to controls (p=0.02), but not in CSF.

Conclusion: Our results suggest that rs199347 is a pQTL for GPNMB CSF levels. Significant elevation of GPNMB in PD patient plasma suggests potential use of GPNMB as a peripheral molecular biomarker for PD. Future studies include validation in additional cohorts and mechanistic studies to understand the mechanism whereby GPNMB levels modulate PD risk.

References: [1] Nalls MA et al., 2014. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nature Genetics46(9):989-93. [2] GTEx Portal (GTEx.org), “eQTL Violin Plot, rs199347” [3] Kramer G et al., 2016. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS Open Bio 6(9):902-913.

To cite this abstract in AMA style:

Y. Seo, M. Diaz Ortiz, D. Weintraub, V. Van Deerlin, J. Trojanowski, A. Chen-Plotkin. GPNMB protein levels in CNS are modulated by PD risk variant rs199347 [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/gpnmb-protein-levels-in-cns-are-modulated-by-pd-risk-variant-rs199347/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/gpnmb-protein-levels-in-cns-are-modulated-by-pd-risk-variant-rs199347/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley